ROLES OF GALL-BLADDER EMPTYING AND INTESTINAL TRANSIT IN THE PATHOGENESIS OF OCTREOTIDE INDUCED GALL-BLADDER STONES

Citation
Sh. Hussaini et al., ROLES OF GALL-BLADDER EMPTYING AND INTESTINAL TRANSIT IN THE PATHOGENESIS OF OCTREOTIDE INDUCED GALL-BLADDER STONES, Gut, 38(5), 1996, pp. 775-783
Citations number
56
Categorie Soggetti
Gastroenterology & Hepatology
Journal title
GutACNP
ISSN journal
00175749
Volume
38
Issue
5
Year of publication
1996
Pages
775 - 783
Database
ISI
SICI code
0017-5749(1996)38:5<775:ROGEAI>2.0.ZU;2-2
Abstract
Background-Octreotide treatment of acromegalic patients increases the % deoxycholic acid conjugates and the cholesterol saturation of gall b ladder bile, and induces gall stone formation. Aims-To study the roles of gall bladder emptying and intestinal transit in these phenomena. M ethods and patients-Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given sa line or 50 mu g of octreotide, and (b) acromegalic patients taking lon g term octreotide. In the second group, large bowel transit was also m easured. Results-A single dose of octreotide inhibited meal stimulated gall bladder emptying, the ejection fraction falling from mean (SEM) 66.0 (2.3)% to 7.0 (5.3)% in controls (p<0.001); from 72.5 (2.1) to 16 .6 (5.1)% in untreated acromegalic patients (p<0.001), and to 30.4 (9. 5)% in acromegalic patients taking long term octreotide (p<0.001 v unt reated acromegalic group). Octreotide prolonged mouth to caecum transi t time, from 112 (15) min to 237 (13) min in controls (p<0.001), from 170 (13) min to 282 (11) min in untreated acromegalic patients (p<0.00 1), and to 247 (10) min in acromegalic patients taking long term octre otide (p<0.001 v untreated acromegalic patients). The mean large bowel transit in octreotide untreated compared with treated acromegalic pat ients remained unchanged (40 (6) h v 47 (6) h). Conclusions-Prolongati on of intestinal transit and impaired gall bladder emptying may contri bute to lithogenic changes in bile composition and gall stone formatio n in patients receiving long term octreotide.